使用文献 |
使用文献募集中!本製品を使って論文を発表されましたら是非お知らせください。
- Noguchi T et al. The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation. Atherosclerosis 210, 166-172 (2010)(PMID:20006333)
- Cariou B et al. Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients. Atherosclerosis 211, 700-702 (2010)(PMID:20452593)
- Costet P et al. Plasma PCSK9 is increased by Fenofibrate and Atorvastatin in a non additive fashion in diabetic patients. Atherosclerosis 212, 246-251 (2010)(PMID:20619837)
- Noguchi T et al. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study. Atherosclerosis 217, 165-70 (2011)(PMID:21411093)
- Mayne J et al. Novel Loss-of-Function PCSK9 Variant Is Associated with Low Plasma LDL Cholesterol in a French-Canadian Family and with Impaired Processing and Secretion in Cell Culture. Clin Chem. 57,1415 (2011)(PMID:21813713)
- Vergès B et al. Lack of association between plasma PCSK9 and LDL-apoB100 catabolism in patients with uncontrolled type 2 diabetes. Atherosclerosis. 219, 342-8 (2011)(PMID:21889145)
- Lena Persson. Studies on PCSK9 in the regulation of cholesterol metabolism. Published by Karolinska Institutet. Stockholm 2011
- Cariou B et al. Clinical aspects of PCSK9. Atherosclerosis. 216, 258-65 (2011)(PMID:21596380)
- Persson L et al. Endogenous Estrogens Lower Plasma PCSK9 and LDL Cholesterol But Not Lp(a) or Bile Acid Synthesis in Women. Arterioscler Thromb Vasc Biol. 32, 810-4 (2011)(PMID:22207727)
- Kawashiri MA et al. Efficacy and Safety of Coadministration of Rosuvastatin, Ezetimibe, and Colestimide in Heterozygous Familial Hypercholesterolemia. Am J Cardiol. 109, 364-9 (2011)(PMID:22112743)
- Lindholm MW et al. PCSK9 LNA Antisense Oligonucleotides Induce Sustained Reduction of LDL Cholesterol in Nonhuman Primates. Mol Ther. 20, 376-81 (2012)(PMID:22108858)
- Cameron J et al. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor_independent pathways. Translational Research. 160, 125-30 (2012)(PMID:22683370)
- Huijgen R et al. Plasma levels of proprotein convertase subtilisin Kexin type 9 (PCSK9) and phenotypic variability in familial hypercholesterolemia. J Lipid Res. 53, 979-83 (2012)(PMID:22375030)
- Cariou B et al. Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets. Nutr Metab. 10, 4 (2013)(PMID:23298392)
- Lee CJ et al. Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects. Metabolism. 62, 845-50 (2013)(PMID:23380568)
- Le Bras M et al. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab. 98, E732-6 (2013)(PMID:23450051)
- Mayne J et al. Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations. Lipids Health Dis. 12, 70 (2013)(PMID:23663650)
- Peticca P et al. Human Serum PCSK9 Is Elevated at Parturition in Comparison to Nonpregnant Subjects While Serum PCSK9 from Umbilical Cord Blood is Lower Compared to Maternal Blood. ISRN Endocrinol. 2013, 341632 (2013)(PMID:23862071)
- Tremblay AJ et al. Short-term, high-fat diet increases the expression of key intestinal genes involved in lipoprotein metabolism in healthy men. Am J Clin Nutr. 98, 32-41 (2013)(PMID:23719552)
- Conway V et al. Impact of buttermilk consumption on plasma lipids and surrogate markers of cholesterol homeostasis in men and women. Nutr Metab Cardiovasc Dis. 23, 1255-62 (2013)(PMID:23786821)
- Lambert G et al. Elevated plasma PCSK9 level is equally detrimental for patients with nonfamilial hypercholesterolemia and heterozygous familial hypercholesterolemia, irrespective of low-density lipoprotein receptor defects. J Am Coll Cardiol. 63, 2365-73 (2014)(PMID:24632287)
- Werner C et al. Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol. 62, 94-102 (2014)(PMID:24685817)
- Abujrad H et al. Chronic kidney disease on hemodialysis is associated with decreased serum PCSK9 levels. Atherosclerosis. 233, 123-9 (2014)(PMID:24529132)
- Jia YJ et al. Short- and long-term effects of Xuezhikang (), an extract of cholestin, on serum proprotein convertase subtilisin/kexin type 9 levels. Chin J Integr Med. (2014)(PMID:24993334)
- Bonde Y et al. Thyroid hormone reduces PCSK9 and stimulates bile acid synthesis in humans. J Lipid Res. 55, 2408-15 (2014)(PMID:25172631)
- Mbikay M et al. Quercetin-3-glucoside increases low-density lipoprotein receptor (LDLR) expression, attenuates proprotein convertase subtilisin/kexin 9 (PCSK9) secretion, and stimulates LDL uptake by Huh7 human hepatocytes in culture. FEBS Open Bio. 4, 755-62 (2014)(PMID:25349780)
- Iggman D et al. Role of dietary fats in modulating cardiometabolic risk during moderate weight gain: a randomized double-blind overfeeding trial (LIPOGAIN study). J Am Heart Assoc. 3, e001095 (2014)(PMID:25319187)
- Xu RX et al. Relation of plasma PCSK9 levels to lipoprotein subfractions in patients with stable coronary artery disease. Lipids Health Dis. 13, 188 (2014)(PMID:25496400)
- Ghosh M et al. Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. J Lipid Res. 56, 463-9 (2015)(PMID:25535288)
- Xu RX et al. Impacts of ezetimibe on PCSK9 in rats: study on the expression in different organs and the potential mechanisms. J Transl Med. 13, 87 (2015)(PMID:25889684)
- Starr AE et al. β-Estradiol results in a proprotein convertase subtilisin/kexin type 9-dependent increase in low-density lipoprotein receptor levels in human hepatic HuH7 cells. FEBS J. 282, 2682-96 (2015)(PMID:25913303)
- Rosqvist F et al. Potential role of milk fat globule membrane in modulating plasma lipoproteins, gene expression, and cholesterol metabolism in humans: a randomized study. Am J Clin Nutr. 102, 20-30 (2015)(PMID:26016870)
- Butkinaree C et al. Amyloid Precursor-like Protein 2 and Sortilin Do Not Regulate the PCSK9 Convertase-mediated Low Density Lipoprotein Receptor Degradation but Interact with Each Other. J Biol Chem. 290, 18609-20 (2015)(PMID:26085104)
- van Pelgeest EP et al. Antisense-mediated reduction of proprotein convertase subtilisin/kexin type 9 (PCSK9): a first-in-human randomized, placebo-controlled trial. Br J Clin Pharmacol. 80, 1350-61 (2015)(PMID:26261033)
- Wassef H et al. The apoB-to-PCSK9 ratio: A new index for metabolic risk in humans. J Clin Lipidol. 9, 664-75 (2015)(PMID:26350813)
- Si-Tayeb K et al. Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia. Dis Model Mech. 9, 81-90 (2016)(PMID:26586530)
- Rogacev KS et al. PCSK9 Plasma Concentrations Are Independent of GFR and Do Not Predict Cardiovascular Events in Patients with Decreased GFR. PLoS One 11, e0146920 (2016)(PMID:26799206)
- Miasan A et al. Effects of LDL Receptor Modulation on Lymphatic Function. Sci Rep. 6, 27862 (2016)(PMID:27279328)
- Vlachopopulos C et al. Prediction of cardiovascular events with levels of proprotein convertase subtilisin/kexin type 9: A systematic review and meta-analysis. Atherosclerosis. 252, 50-60 (2016)(PMID:27501130)
- Li S et al. Novel circulating lipid measurements for current dyslipidemias in non-treated patients undergoing coronary angiography: PCSK9, apoC3 and sdLDL-C. Oncotarget 8, 12333-12341 (2017)(PMID:27713142)
- Navarese EP et al. Association of PCSK9 with platelet reactivity in patients with acute coronary syndrome treated with prasugrel or ticagrelor: The PCSK9-REACT study. Int J Cardiol. 227, 644-649 (2017)(PMID:27810295)
- Suzuki Y et al. Biodegradable lipid nanoparticles induce a prolonged RNA interference-mediated protein knockdown and show rapid hepatic clearance in mice and nonhuman primates. Int J Pharm. 519, 34-43 (2017)(PMID:28089936)
- Li S et al. Novel and traditional lipid-related biomarkers and their combinations in predicting coronary severity. Sci Rep. 7, 360 (2017)(PMID:28336922)
- Hyrina A et al. Treatment-Induced Viral Cure of Hepatitis C Virus-Infected Patients Involves a Dynamic Interplay among three Important Molecular Players in Lipid Homeostasis: Circulating microRNA (miR)-24, miR-223, and Proprotein Convertase Subtilisin/Kexin Type 9. EBioMedicine. 23, 68-78 (2017)(PMID:28864162)
- Blanchard C et al. Roux-en-Y gastric bypass reduces plasma cholesterol in diet-induced obese mice by affecting trans-intestinal cholesterol excretion and intestinal cholesterol absorption. Int J Obes. (2017) In press.(PMID:29135972)
- Iacocca MA et al. Whole-Gene Duplication of PCSK9 as a Novel Genetic Mechanism for Severe Familial Hypercholesterolemia. Can J Cardiol. 34, 1316-1324 (2018)(PMID:30269829)
- Zhang Z et al. Sex Differences Associated With Circulating PCSK9 in Patients Presenting With Acute Myocardial Infarction. Sci Rep. 9, 3113 (2019)
(PMID:30816133)
- Merrelaar A et al. Low PCSK-9 levels Are Associated with Favorable Neurologic Function after Resuscitation from out of Hospital Cardiac Arrest. J Clin Med. 9, 2606 (2020)(PMID:32796672)
|